Doramectin efficacy against Psoroptes ovis in sheep: Evaluation of pharmacological strategies.


Journal

Experimental parasitology
ISSN: 1090-2449
Titre abrégé: Exp Parasitol
Pays: United States
ID NLM: 0370713

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 17 04 2020
revised: 27 08 2020
accepted: 13 09 2020
pubmed: 18 9 2020
medline: 11 11 2020
entrez: 17 9 2020
Statut: ppublish

Résumé

The aims of this study were to evaluate the efficacy of two injectable formulations of doramectin (DRM) against Psoroptes ovis in sheep infested under controlled experimental conditions and to characterize the DRM plasma disposition kinetics in the infested animals. To this end, sheep were experimentally infested with a P. ovis strain from a farm with a history of treatment failure, and then treated either with DRM 1% (traditional preparation) on days 0 and 7 or with DRM 3.15% (long-acting formulation) on day 0. The efficacy of each treatment was calculated by counting live mites in skin scrapings. Plasma samples were obtained from each animal and DRM concentrations were measured by HPLC. After the two doses of DRM 1%, the maximum efficacy (98.8%) was reached on day 28, whereas after the single dose of DRM 3.15%, the maximum efficacy (100%) was reached on day 35 and ratified on day 42. The long-acting formulation allowed obtaining higher exposure and more sustained concentrations of DRM than the traditional preparation. Although both DRM formulations studied were effective according to international protocols, they did not reach 100% effectiveness in the time required for approved pharmaceutical products against sheep scab, according to Argentine regulations.

Identifiants

pubmed: 32941889
pii: S0014-4894(20)30196-X
doi: 10.1016/j.exppara.2020.107998
pii:
doi:

Substances chimiques

Insecticides 0
Ivermectin 70288-86-7
doramectin KGD7A54H5P

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107998

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

M Larroza (M)

Grupo de Salud Animal, Instituto Nacional de Tecnología Agropecuaria (INTA), Modesta Victoria 4450, 8400, Bariloche, Argentina.

P Soler (P)

Grupo de Salud Animal, Instituto Nacional de Tecnología Agropecuaria (INTA), Modesta Victoria 4450, 8400, Bariloche, Argentina.

C Robles (C)

Grupo de Salud Animal, Instituto Nacional de Tecnología Agropecuaria (INTA), Modesta Victoria 4450, 8400, Bariloche, Argentina.

R Cabrera (R)

Grupo de Salud Animal, Instituto Nacional de Tecnología Agropecuaria (INTA), Modesta Victoria 4450, 8400, Bariloche, Argentina.

M Ballent (M)

Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN) (UNCPBA-CICPBA-CONICET), Facultad de Ciencias Veterinarias, UNCPBA, Tandil, Argentina.

C Lanusse (C)

Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN) (UNCPBA-CICPBA-CONICET), Facultad de Ciencias Veterinarias, UNCPBA, Tandil, Argentina.

A Lifschitz (A)

Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN) (UNCPBA-CICPBA-CONICET), Facultad de Ciencias Veterinarias, UNCPBA, Tandil, Argentina. Electronic address: adrianl@vet.unicen.edu.ar.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH